Pelthos Therapeutics Inc.PTHSEarnings & Financial Report
NYSE · Health Care · Biological Products, (No Diagnostic Substances)
Pelthos Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for rare metabolic and endocrine diseases with significant unmet medical needs. It operates primarily across North America and Europe, with a pipeline of novel drug candidates addressing underserved patient populations.
PTHS Q3 FY2025 Key Financial Metrics
Revenue
$294.0K
Gross Profit
$-2.0M
Operating Profit
$-15.4M
Net Profit
$-16.2M
Gross Margin
-687.8%
Operating Margin
-5225.2%
Net Margin
-5523.1%
YoY Growth
N/A
EPS
$-5.30
Pelthos Therapeutics Inc. Q3 FY2025 Financial Summary
Pelthos Therapeutics Inc. reported revenue of $294.0K for Q3 FY2025, with a net profit of $-16.2M (down 858.0% YoY) (-5523.1% margin). Cost of goods sold was $2.3M, operating expenses totaled $13.3M.
Key Financial Metrics
| Total Revenue | $294.0K |
|---|---|
| Net Profit | $-16.2M |
| Gross Margin | -687.8% |
| Operating Margin | -5225.2% |
| Report Period | Q3 FY2025 |
Income Statement
| Q3 2025 | |
|---|---|
| Revenue | $294000 |
| YoY Growth | N/A |
Balance Sheet
| Q3 2025 | |
|---|---|
| Assets | $126.4M |
| Liabilities | $68.2M |
| Equity | $58.3M |
Cash Flow
| Q3 2025 | |
|---|---|
| Operating CF | $-15.3M |